Procarta Biosystems was developing a pipeline of oligonucleotide-based antibacterials from its Oligonucleotide Antimicrobial platform, a novel proprietary nanoparticle approach targeting a new class of antibiotics targets, transcription factors. Procarta’s lead asset, PRO-202, was in preclinical development to treat complicated urinary tract infections (cUTI) and complicated intraabdominal infections (cIAI).